The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback